- Home
- OBIO vs ENTA Comparison
OBIO vs ENTA Comparison
Compare OBIO & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- ENTA
- Stock Information
- Founded
- OBIO 2017
- ENTA 1995
- Country
- OBIO United States
- ENTA United States
- Employees
- OBIO N/A
- ENTA N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- OBIO Health Care
- ENTA Health Care
- Exchange
- OBIO Nasdaq
- ENTA Nasdaq
- Market Cap
- OBIO 172.1M
- ENTA 164.6M
- IPO Year
- OBIO N/A
- ENTA 2013
- Fundamental
- Price
- OBIO $4.00
- ENTA $10.75
- Analyst Decision
- OBIO Strong Buy
- ENTA Strong Buy
- Analyst Count
- OBIO 4
- ENTA 5
- Target Price
- OBIO $14.00
- ENTA $21.00
- AVG Volume (30 Days)
- OBIO 351.1K
- ENTA 1.6M
- Earning Date
- OBIO 11-11-2025
- ENTA 11-24-2025
- Dividend Yield
- OBIO N/A
- ENTA N/A
- EPS Growth
- OBIO N/A
- ENTA N/A
- EPS
- OBIO N/A
- ENTA N/A
- Revenue
- OBIO $2,944,000.00
- ENTA $64,806,000.00
- Revenue This Year
- OBIO $29.26
- ENTA $0.07
- Revenue Next Year
- OBIO $10.65
- ENTA N/A
- P/E Ratio
- OBIO N/A
- ENTA N/A
- Revenue Growth
- OBIO 41.61
- ENTA N/A
- 52 Week Low
- OBIO $2.20
- ENTA $4.09
- 52 Week High
- OBIO $6.50
- ENTA $15.34
- Technical
- Relative Strength Index (RSI)
- OBIO 67.99
- ENTA 52.20
- Support Level
- OBIO $3.53
- ENTA $10.20
- Resistance Level
- OBIO $4.04
- ENTA $11.59
- Average True Range (ATR)
- OBIO 0.33
- ENTA 0.60
- MACD
- OBIO 0.07
- ENTA -0.18
- Stochastic Oscillator
- OBIO 94.20
- ENTA 25.77
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.